Can Abbott’s connected neuromodulation platforms improve life for chronic pain and movement disorder patients? (opens in new tab)

<p>In the final episode of AbbottTalks season 3, hosts Tom Salemi and Kayleen Brown sit down with Rebecca Wilkins, divisional vice president of R&amp;D for Abbott’s Neuromodulation business, to discuss the technologies Abbott is advancing for chronic pain and movement disorders.<br /><br />Wilkins explains how Abbott’s spinal cord stimulation platforms, Proclaim™ DRG Neurostimulation System, and Infinity™ deep brain stimulation system are designed to interrupt errant nervous system signals, h...